Bioanalytical approach to the interaction of novel sym-triazine derivatives with Alzheimer's disease biomarkers
Year: 2015
Type: dissertation
Abstract: Alzheimer's Disease (AD) is a complex neurological disorder affecting an increasing number of people worldwide. The amyloid hypothesis is the most widely accepted theory for the cause of AD and states that the main origin of the disease stems from the mis-folding and accumulation of the amyloid-beta peptide (Aβ). There is currently no cure for the disease, however, drugs are available to mitigate the symptoms. Multi-target directed ligands (MTDLs) have been implemented as a novel drug design strategy for treatment of AD. sym-Triazine derivatives have been previously reported as effective inhibitors of Aβ aggregation and acetylcholinesterase (AChE). Two novel sym-triazine derivatives (AM-1 and AM-2) have been synthesized, that improve on previous design and were tested for their inhibition through various analytical techniques. The results indicate that the novel compounds were more effective in Aβ aggregation but not as potent in their AChE inhibition in comparison to previous derivatives.
Source: TSpace (University of Toronto)
Author: Amy Liu
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2726948584